Methyl donor supplement
Betaine Anhydrous (TMG)
Betaine had an elimination half-life of 14.38 h (s.d. 7.17) after a single dose in a 2003 study of 12 healthy men; the app lists 14 hours.1
Betaine Anhydrous (TMG) after one dose: 50% at ~14 h, 25% at 28 h, 12.5% at 42 h.
Drawn from the half-life in the app's model, ~14 h. The model's figures
- Compound
- Betaine Anhydrous (TMG)
- Symbol
- TMG
- Family
- Supplements
- Parts
- 14
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Betaine anhydrous, chemically named trimethylglycine (TMG), is the active ingredient of a US powder for oral solution, and the app's notes describe it as a standard ingredient in pre-workouts.2 The US label of one betaine anhydrous product states that it "is indicated for the treatment of homocystinuria to decrease" elevated homocysteine blood concentrations in pediatric and adult patients.2 The label lists three forms of homocystinuria: cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency and a cobalamin cofactor metabolism (cbl) defect.2 The label gives "Initial U.S. Approval: 1996".2 The app lists the compound as a methyl donor supplement and notes its use as a pre-workout ingredient; the app grades its evidence as moderate.
How it works
Sources in this part
The label states that betaine "acts as a methyl group donor" in the remethylation of homocysteine to methionine in patients with homocystinuria.2 It also says betaine occurs naturally in the body and is a metabolite of choline.2 Zawieja and colleagues write that "The two main roles of BET in the body are osmoregulation and methyl group donation".3 They describe homocysteine being methylated to methionine, "which is then converted to S-adenosylmethionine (SAM)".3 The same authors state that the mechanisms of its possible effect on exercise "remain incompletely understood".3 Cholewa and colleagues discuss, as possibilities and not as findings, that betaine "may be ergogenic as an osmolyte" and that gains in lean mass "may have been due to cellular swelling without an appreciable increase in myofibril protein accretion".4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~14 h
- Bioavailability
- 99%
- Typical dose
- 2.5 g/day
- Route
- Oral
- Time to peak
- ~1 h
The label states that "Pharmacokinetic studies of Betaine Anhydrous for Oral Solution are not available".2 The figures below come from research studies, not from the label.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~14 h | 14.38 h (s.d. 7.17) after one dose of 50 mg betaine per kg in 12 healthy men, and 41.17 h (s.d. 13.50) during twice-daily intake of the same dose;1 medians of 12.3 to 18.4 h across four groups of 5 to 6 children with CBS or cblC deficiency after a single dose of 100 or 250 mg/kg6 |
| Time to peak | ~1 h | Tmax of 0.90 h (s.d. 0.33) in healthy men;1 median Tmax of 2 h in the children, with no samples drawn between 0 and 2 h6 |
| Bioavailability | 99% | The label states that plasma betaine concentrations after its product "have not been measured in patients";2 urinary excretion of betaine equalled 4% of the ingested dose in healthy men;1 no figure for oral bioavailability is given in the sources read |
Schwahn and colleagues, in a 2003 study of 12 healthy men, report rapid absorption (absorption half-life 0.28 h, s.d. 0.17) and conclude that "Betaine is mainly eliminated by metabolism".1 Their record states that "Distribution and elimination kinetics in homocystinuric patients appeared to be accelerated".1 The half-life of 14.38 h therefore matches the app's figure of 14 h only for a single dose; after repeated dosing the same study reports 41.17 h.1 Schwab and colleagues, Journal of Nutrition, 2006, gave 10 healthy volunteers single doses of 1, 3 and 6 g and report that "The absorption and elimination of betaine were dose dependent".5 They also report that "a very small proportion of ingested betaine was excreted via urine".5 Atkinson and colleagues, American Journal of Clinical Nutrition, 2008, studied 8 healthy men and report that "no significant betaine appeared in the urine".7
Human studies
The studies below are in people. Three are described in more detail afterwards.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Label clinical study, Eton label (2023)2 | Double-blind, placebo-controlled crossover | 6 patients with CBS deficiency, ages 7 to 32 years | 3 grams twice daily for 12 months | Plasma homocystine significantly reduced against placebo; plasma methionine "variable and not significantly different"2 |
| Schwab and colleagues, J Nutr 20065 | Randomised, double-blind crossover; single doses | 10 healthy volunteers (3 men, 7 women) | 1, 3 or 6 g once, mixed with 150 mL orange juice | Single doses of 3 and 6 g lowered plasma total homocysteine, the 1 g dose did not; the change was linearly associated with dose5 |
| Atkinson and colleagues, Am J Clin Nutr 20087 | Randomised crossover | 8 healthy men aged 19 to 40 | Betaine supplement of about 500 mg, once per condition | Plasma betaine rose; "Small decreases in plasma homocysteine 6 h after ingestion" followed a high-betaine meal and a high-betaine and high-choline meal; rise after a methionine load was attenuated7 |
| Schwab and colleagues, Am J Clin Nutr 20028 | Randomised, placebo-controlled, on a hypoenergetic diet | 42 obese white adults (14 men, 28 women) | 6 g/day or placebo for 12 weeks | Body weight, resting energy expenditure and fat mass fell in both groups with no significant difference between them; homocysteine fell in the betaine group; total and LDL cholesterol were higher on betaine8 |
| McRae, J Chiropr Med 20139 | Meta-analysis of 5 randomised placebo-controlled trials | Healthy adults | At least 4 g/d for 6 to 24 weeks | Pooled homocysteine reduction of 1.23 μmol/L; all 5 trials began with normal homocysteine9 |
| Zawieja and colleagues, J Diet Suppl 202110 | Meta-analysis of 6 randomised placebo-controlled trials | Adults | At least 4 g/d for 6 to 24 weeks | Total cholesterol higher by 0.34 mmol/L (95% CI 0.02, 0.65) than placebo; no significant effect on LDL, HDL or triglycerides10 |
| Imbard and colleagues, Orphanet J Rare Dis 20226 | Randomised crossover, blinded evaluation | 11 children with pyridoxine non-responsive CBS (5) or cblC (6) deficiency; the authors list the small number of patients as a limitation | 100 versus 250 mg/kg/day, one month each | Total homocysteine equivalent between the two doses; betaine dose affected methionine and S-adenosylmethionine6 |
| Grizales and colleagues, J Clin Endocrinol Metab 201811 | Randomised, double-masked, placebo-controlled, parallel | 27 adults with obesity and prediabetes | 3300 mg twice daily for 10 days, then 4950 mg twice daily for 12 weeks | Insulin sensitivity by clamp "was not improved"; total cholesterol rose against placebo (P = 0.032); no serious adverse events11 |
| del Favero and colleagues, Amino Acids 201212 | Double-blind, randomised, placebo-controlled | Untrained subjects | Betaine 2 g/day, creatine 20 g/day, both, or placebo for 10 days | Muscle phosphorylcreatine and strength or power did not differ between betaine and placebo12 |
| Cholewa and colleagues, J Int Soc Sports Nutr 20134 | Randomised, placebo-controlled, with periodised training | 23 strength-trained men | 2.5 g/day or placebo for 6 weeks | Body composition and arm size improved on betaine; no differences in bench press, squat or vertical jump performance between groups4 |
| Ismaeel, J Strength Cond Res 201713 | Systematic review of randomised trials | Healthy participants | Varied | In 7 trials, only 2 reported increases in strength or power; 5 showed no change13 |
| Zawieja and colleagues, J Int Soc Sports Nutr 20233 | Double-blind randomised crossover | 43 male CrossFit practitioners who completed it (55 randomised) | 2.5 or 5.0 g/day versus placebo, 3 weeks each | CrossFit test total improved 8.7 ± 13.6% on betaine and changed -0.4 ± 10.0% on placebo; no change in Wingate power or body composition; total testosterone up 7.0 ± 15.4% on betaine against 1.5 ± 19.6% on placebo, and the authors say the significance of the 7% rise may be questioned3 |
| Nieman and colleagues, Nutrients 202514 | Randomised, double-blind, placebo-controlled crossover | 21 male and female non-elite cyclists | 3 g/day, 2 weeks each, 2-week washout | 60 km time (mean ± SE) 112.8 ± 2.3 min on betaine versus 114.2 ± 2.6 min on placebo; no difference in gut permeability marker or cortisol; total body intracellular water decreased on betaine compared with placebo14 |
Sources in this part
Deeper analysis: Schwahn 2003, pharmacokinetics
Schwahn and colleagues, Department of Paediatrics, Heinrich-Heine-University Düsseldorf, reported an open-label study in the British Journal of Clinical Pharmacology in 2003.1 Twelve male volunteers received a single dose of 50 mg betaine per kg and then twice-daily 50 mg/kg, and three patients with homocystinuria received a single dose.1 Cmax was 0.94 mmol/L (s.d. 0.19) at 0.90 h (s.d. 0.33), and the elimination half-life was 14.38 h (s.d. 7.17) after the single dose.1 After repeated dosing the elimination half-life rose to 41.17 h (s.d. 13.50), and dimethylglycine "accumulation occurred to the same extent as with betaine".1 The PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and does not name a funder or any author tie to a sponsor.1 Only three patients were studied, and the authors write that "More pharmacokinetic and pharmacodynamic studies in hyperhomocysteinaemic patients are needed to refine the current treatment with betaine."1
Deeper analysis: Cholewa 2013, six weeks in strength-trained men
Cholewa and colleagues, Coastal Carolina University and collaborators, reported the trial in the Journal of the International Society of Sports Nutrition in 2013.4 Twenty-three men with 4.8 ± 2.3 years of training were randomly assigned to placebo (n = 12) or betaine 2.5 g/day (n = 11) alongside a 6 week periodised program of three 2-week micro-cycles.4 Outcomes included training volume, limb size estimated from girth and skin-fold measures, body composition, vertical jump and 1 RM bench press and squat.4 Arm CSA increased in the betaine group but not in placebo, and thigh CSA did not differ between groups.4 Bench press volume improved more on betaine at micro-cycle one (7.89 ± 2.65% against 0.49 ± 1.69%, p = .001) and micro-cycle three, but the placebo group improved more at micro-cycle two (19.2 ± 11.2% against 5.9 ± 1.4%, p = .001).4 The paper reports no difference in 1 RM bench press, 1 RM squat or vertical jump between groups, with "a trend (p = .07)" for vertical jump power.4 Urinary homocysteine thiolactone rose in the placebo group from baseline to week 2 but not on betaine.4 The authors name limits: the limb-size method has a standard error of estimate of 3.25 cm2 against a 4.6 cm2 arm change, and subject diets "were not analyzed for micronutrients".4 DuPont Nutrition & Health provided funding, and one author (S.A.S.C.) is employed by DuPont Nutrition & Health.4 The authors conclude that "Further work is warranted" on the role of homocysteine thiolactone compared with other mechanisms.4
Deeper analysis: Zawieja 2023, CrossFit crossover
Zawieja and colleagues, Poznan University of Life Sciences and Poznan University of Physical Education, reported the trial in the Journal of the International Society of Sports Nutrition in 2023, registered as NCT03702205.3 Fifty-five men aged 18 to 45 were randomised and 43 completed; the paper lists 11 dropouts, 6 of them for COVID-19 isolation or quarantine, although 55 minus 43 is 12.3 Each took betaine and placebo for three weeks with a three-week washout, at 2.5 g/day (n = 24) or 5.0 g/day (n = 19).3 The main outcome was a 17-minute "Fight Gone Bad" workout, with a 30-second Wingate test, air-displacement body composition, hormones and MTHFR genotype as other measures.3 The workout total improved by 8.7 ± 13.6% on betaine, against -0.4 ± 10.0% on placebo (p = 0.128 within placebo).3 Wingate power, body composition, insulin-like growth factor and cortisol did not change, and total testosterone rose 7.0 ± 15.4% on betaine (p = 0.046) against 1.5 ± 19.6% on placebo.3 There was no evidence of a difference between the two doses or between MTHFR genotypes, "although smaller differences, which were undetected here, could still exist".3 The authors write that "No side effects were reported throughout the study".3 Their stated limitations include that folate status was not measured, supplementation "could have been too short" to show body composition changes, and only total, not free, testosterone was measured; they say the physiological significance of the 7% rise "may be questioned".3 The research was funded by the Polish National Science Centre, and the authors report "No potential conflict of interest".3
Deeper analysis: Nieman 2025, 60 km cycling
Nieman and colleagues, Human Performance Laboratory, Appalachian State University, reported the trial in Nutrients in 2025.14 Of 41 people assessed, 23 entered and 21 completed; they took 3 g/day (6 capsules of 500 mg) or placebo for two weeks each with a two-week washout, then rode a 60 km time trial.14 Time to finish was 112.8 ± 2.3 min on betaine and 114.2 ± 2.6 min on placebo (mean ± SE; difference -1.41 ± 0.7 min, effect size 0.475, p = 0.042).14 There were no trial differences in the gut permeability marker I-FABP (p = 0.076), the lactulose to mannitol ratio (p = 0.559), the neutrophil/lymphocyte ratio, serum cortisol (p = 0.982), myoglobin (p = 0.942) or creatine kinase (p = 0.694).14 Total body intracellular water changed differently between trials (interaction p = 0.010), decreasing on betaine compared with placebo, and extracellular water did not differ (p = 0.640).14 Untargeted metabolomics linked betaine to higher plasma betaine, dimethylglycine, sarcosine, methionine and S-adenosylhomocysteine and to lower plasma carnitine and numerous acylcarnitines.14 The authors conclude that betaine "modestly improved 60 km cycling performance" and list limitations: modest gut permeability changes after the ride, no cytokine or epigenetic measures, and a larger dose over a longer period "remains to be determined".14 AGRANA Beteiligungs-AG, Vienna, funded the research and its study sponsor prepared both the betaine and placebo capsules; the authors declare no conflicts of interest and state that the funders had no role in design, analysis or the decision to publish.14
Deeper analysis: Grizales 2018, prediabetes
Grizales and colleagues reported a 12-week trial of 27 adults with obesity and prediabetes in the Journal of Clinical Endocrinology and Metabolism in 2018.11 Plasma dimethylglycine rose 16.5-fold against placebo, while serine and methionine rose 1.3- and 1.5-fold.11 Fasting glucose tended lower (P = 0.08), insulin area under the curve after oral glucose was lower (P = 0.038), insulin sensitivity by clamp was not improved, and intrahepatic triglyceride and endothelial function did not differ.11 The authors cite "the small study population, relatively short duration of betaine administration, and multiple end points" as context for the findings.11 The record lists NIDDK and NCATS grants and the authors state "The authors have nothing to disclose."11
Doses reported in studies and on labels
| Source | Population | Dose and route | Length | Comparator |
|---|---|---|---|---|
| Eton label2 | Adults and children 3 years and older with homocystinuria | 6 grams per day by mouth, as 3 grams twice daily | Not stated | None stated |
| Eton label2 | Children under 3 years with homocystinuria | Starting 100 mg/kg/day by mouth, raised weekly by 50 mg/kg | Not stated | None stated |
| Eton label2 | Some patients with homocystinuria | Up to 20 grams/day by mouth | Not stated | None stated |
| Schwahn 20031 | 12 healthy men | 50 mg/kg once, then twice daily, by mouth | 5 days of continuous intake | None |
| Schwab 20065 | 10 healthy volunteers | 1, 3 or 6 g once, by mouth in orange juice | Single dose | Crossover between doses |
| Atkinson 20087 | 8 healthy men | About 500 mg once, by mouth | Single dose | Control meal |
| Schwab 20028 | 42 obese adults | 6 g/day by mouth | 12 weeks | Placebo |
| Imbard 20226 | 11 patients with CBS or cblC deficiency | 100 versus 250 mg/kg/day by mouth | One month each | The other dose |
| Grizales 201811 | 27 adults with prediabetes | 3300 mg twice daily, then 4950 mg twice daily, by mouth | 10 days, then 12 weeks | Placebo |
| del Favero 201212 | Untrained subjects | 2 g/day by mouth | 10 days | Placebo |
| Cholewa 20134 | 23 strength-trained men | 2.5 g/day by mouth | 6 weeks | Placebo |
| Zawieja 20233 | 43 male CrossFit practitioners | 2.5 or 5.0 g/day by mouth, in 500 mg capsules | 3 weeks | Placebo (cellulose) |
| Nieman 202514 | 21 cyclists | 3 g/day by mouth, in 500 mg capsules | 2 weeks | Placebo capsules |
The app lists a typical dose of 2.5 g/day, which matches the dose in the Cholewa and Zawieja trials and is below the label's 6 grams per day for homocystinuria.4,3,2
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: twice daily (label)2.
An illustration from a pharmacokinetic model using a half-life of 14 hours. It is not a measured level or a suggested dose.
Side effects reported
The label's adverse reaction list comes from "a survey study of 41 physicians" covering 111 patients with homocystinuria, in which reactions "were retrospectively recalled and were not collected systematically".2 The label names nausea and gastrointestinal distress as the most common reactions in that survey.2 It reports "Severe cerebral edema and hypermethioninemia" within 2 weeks to 6 months of starting therapy, with complete recovery after stopping, and says all affected patients had CBS deficiency with severe elevation in plasma methionine.2 The label also lists post-marketing reactions such as anorexia, agitation, depression and urinary incontinence, reported from a population of uncertain size.2 In the crossover trial of Imbard and colleagues, 8 of 11 patients had one to 5 "minor adverse events", including gastrointestinal disorder (3 at each dose); the paper adds that one patient, whose minor events were present before the study, also had seizures during the wash-out period.6 The authors conclude that doses above 100 mg/kg/day "could be harmful" in pyridoxine non-responsive CBS deficiency with pre-existing hypermethioninemia.6 Zawieja and colleagues reported no side effects in 43 healthy CrossFit practitioners over three weeks, and Grizales and colleagues reported no serious adverse events and "sparse" nonserious events balanced between groups in 27 adults with prediabetes.3,11 Total cholesterol was higher on betaine in a meta-analysis at 4 g/day or more (0.34 mmol/L, 95% CI 0.02 to 0.65) and in two single trials.10,8,11
Bloodwork and markers
Sources in this part
The app lists homocysteine as the marker to monitor.2 The label says patient response is monitored by plasma homocysteine concentrations, and that in CBS deficiency plasma methionine is also monitored.2 The label reports that an initial response in homocysteine "usually occurs within several days" and that steady state occurs "within a month" in patients with homocystinuria.2 Single doses of 3 and 6 g lowered plasma total homocysteine in healthy volunteers within 2 hours, and after 6 g concentrations "remained low during the 24 h of monitoring".5 The McRae meta-analysis pooled a homocysteine reduction of 1.23 μmol/L in healthy adults at 4 g/day or more, and its author notes that the decrease is smaller in healthy volunteers than in patients with hyperhomocysteinaemia.9 Total testosterone rose by 7.0 ± 15.4% on betaine against 1.5 ± 19.6% on placebo in Zawieja 2023, free testosterone was not measured, and the authors say the physiological significance of the 7% rise may be questioned.3
Regulatory and anti-doping status
Sources in this part
The Eton betaine anhydrous label gives "Initial U.S. Approval: 1996" for homocystinuria.2 The text of the WADA 2026 Prohibited List, which covers classes S0 to S9, the prohibited methods and P1, does not contain the word betaine or trimethylglycine.15 The list states that its Monitoring Program substances are "not considered Prohibited Substances", and betaine is not named in that passage either.15 This is a reading of the list text only; it is not a statement from WADA or an anti-doping organisation about betaine products.15 Several classes on the list also cover "and other substances with a similar chemical structure or similar biological effect(s)", which a search for the names betaine and trimethylglycine does not address.15
Storage and handling
Sources in this part
What is not known
The label states that plasma betaine concentrations after its product have not been measured in patients and "have not been correlated to homocysteine concentration".2 Searches of PubMed on oral absorption and bioavailability returned no record, so the app's bioavailability of 99% has no figure from the sources read to compare against. The exercise trials disagree: Ismaeel reports that only 2 of 7 trials found increases in strength or power, and Zawieja 2023 found a gain in a workout test but none in Wingate power.13,3 Ismaeel concluded that the review "highlights the lack of evidence for a clear ergogenic effect".13 The review adds that 2 studies did identify increases of up to 24.61% in strength and power, and that additional studies are necessary to evaluate effectiveness.13 The app's note says betaine boosts power output, strength and body composition via cellular hydration and SAM-e regeneration, and the trials are mixed on it: del Favero (2 g/day for 10 days) found no difference from placebo in strength or power and no body composition difference, Zawieja 2023 found no change in Wingate power or body composition but a gain in a workout test, and Cholewa reported improved body composition in strength-trained men.12,3,4 The label states that long-term carcinogenicity and fertility studies have not been conducted with its product, that there is no information on overdose in humans, and that animal reproduction studies have not been conducted.2
Frequently asked questions
What is the half-life of betaine anhydrous (TMG)?
How long does betaine take to reach its peak level?
The 2003 study reported a time to maximum concentration of 0.90 h (s.d. 0.33), and the app lists about 1 hour.1
Is betaine anhydrous (TMG) banned by WADA?
Is trimethylglycine the same as betaine anhydrous?
The label gives the chemical name of betaine anhydrous powder as trimethylglycine.2
What is the bioavailability of betaine?
What is betaine anhydrous approved for in the United States?
The Eton label lists it for homocystinuria, to decrease elevated homocysteine blood concentrations in pediatric and adult patients.2
Does betaine lower homocysteine?
In a meta-analysis of five trials in healthy adults at 4 g/day or more, betaine lowered plasma homocysteine by 1.23 μmol/L.9 The label reports homocysteine decreases of 71 to 83% in patients with homocystinuria from a review of 16 case studies and one randomised trial, with no formal statistical analyses, and many of these patients also took other therapies.2
Does betaine improve strength or power?
A systematic review of seven trials found that only 2 reported increases in strength or power and 5 showed no change.13
Does betaine raise cholesterol?
A meta-analysis of six trials at 4 g/day or more reported total cholesterol 0.34 mmol/L higher than placebo (95% CI 0.02, 0.65), with no significant effect on LDL, HDL or triglycerides.10
Guides, tools and comparisons
References
- Schwahn BC, et al. Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br J Clin Pharmacol 2003. PMID 12534635
- Eton Pharmaceuticals. Betaine Anhydrous for Oral Solution. US prescribing information (DailyMed, version 7, issued 02/2023). DailyMed label
- Zawieja E, et al. Betaine supplementation improves CrossFit performance and increases testosterone levels, but has no influence on Wingate power: randomized crossover trial. J Int Soc Sports Nutr 2023. PMC10327519
- Cholewa JM, et al. Effects of betaine on body composition, performance, and homocysteine thiolactone. J Int Soc Sports Nutr 2013. PMC3844502
- Schwab U, et al. Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. J Nutr 2006. PMID 16365055
- Imbard A, et al. Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial. Orphanet J Rare Dis 2022. PMC9664596
- Atkinson W, et al. Dietary and supplementary betaine: acute effects on plasma betaine and homocysteine concentrations under standard and postmethionine load conditions in healthy male subjects. Am J Clin Nutr 2008. PMID 18326594
- Schwab U, et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002. PMID 12399266
- McRae MP. Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis. J Chiropr Med 2013. PMC3610948
- Zawieja EE, et al. Betaine Supplementation Moderately Increases Total Cholesterol Levels: A Systematic Review and Meta-Analysis. J Diet Suppl 2021. PMID 31809615
- Grizales AM, et al. Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes. J Clin Endocrinol Metab 2018. PMC6692715
- del Favero S, et al. Creatine but not betaine supplementation increases muscle phosphorylcreatine content and strength performance. Amino Acids 2012. PMID 21744011
- Ismaeel A. Effects of Betaine Supplementation on Muscle Strength and Power: A Systematic Review. J Strength Cond Res 2017. PMID 28426517
- Nieman DC, et al. Betaine Supplementation Improves 60 km Cycling Time Trial Performance and One-Carbon Metabolism in Cyclists During Recovery. Nutrients 2025. PMC12430687
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list